CureVac anticipates funding will last until 2028
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Cash Position: As of September 30, 2025, cash and cash equivalents amounted to EUR 416.1 million, down from EUR 481.7 million at the end of 2024.
Use of Cash: The cash was primarily utilized for operating activities, focusing on research and development in oncology precision immunotherapies and mRNA technology.
Decrease in Cash Outflow: Cash outflow significantly decreased compared to the same period in 2024, attributed to the absence of extraordinary payments from the previous year and cost-saving measures from a strategic restructuring.
Future Outlook: The company reaffirms its expected cash runway extending into 2028.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
